2022 could signal a breakout year during which the company seeks to take the rapid detection of bacterial and infectious disease to the next level...
Strong earnings reports from these semiconductor stocks could lead to more upside. The post Best Growth Stocks To Buy Now? 4 Semiconductor Stocks For Your List...
In this past weekend's newsletter, I discussed the rarity of 6-positive market months in a row. To wit: "An additional 'red flag' is the S&P 500...
These virtual reality stocks should head higher as new devices hit the market. The VR industry is expanding at a fast pace. The post The 5...
For the first time in several months, inflation in the US has moderated, indicating that price pressures in some areas have weakened. Big questions remain over...
Would these cybersecurity stocks be sound investments amidst the current focus on digital security? The post Best Stocks To Buy Now? 5 Cybersecurity Stocks To Watch...
AMC stock surge triggers momentum for 3 Reddit penny stocks The post Best Penny Stocks To Buy Now? 3 Reddit Stocks To Watch After AMC Pop...
Canadian biotech Medicago has the data it was hoping for from a phase 2 trial of its COVID-19 The post Medicago, GSK’s plant-made COVID jab clears...
Twilio (TWLO), which is a provider of APIs and other technologies for communications, did not impress Wall Street with its quarterly report on May 5. On...
Metals are one of the big winners of the last few weeks as demand has surged
Fed holds the course Investors moved back into the global recovery trade overnight as the Federal Reserve stayed “on message” and was suitably dovish at its...
Shares of Facebook (FB) jumped 6.2% in Wednesday’s extended trading session after the social networking service company posted 1Q results that surpassed analysts’ expectations by a...
World Psychedelics Day (WPD), launches Sunday, June 20th celebrating a new era of informed perspectives on modern-day psychedelics and breakthroughs in treatment of mental health.
TSLA, SPACs, and the EV Craze Attracting More Investors Than Ever
Tired of the COVID-19 Lockdown? Here is a Responsible Reopening Plan
Gilead Shares Dip on Leaked Trial Data Showing No ‘Benefit’ of Antiviral Drug